On January 17, 2023, BYND Cannasoft Enterprises Inc. (Nasdaq: BCAN) announced that in addition to the US Provisional Patent Application with serial number 63/297,009 that was filed on January 6, 2022, covering the monitoring and controlling aspects of its EZ-G device, the company filed a full-scale PCT application on January 5, 2023, under serial number PCT/IL2023/050016.
The PCT application is based on BYND Cannasoft’s prototype of the EZ-G device that is currently under development and its operational aspects as a learning adult device. The PCT application further claims priority from the US Provisional application and covers an adult device with a structure and one or more moving and vibrating elements.
In addition to potentially treating annoying phenomena in the female reproductive system, the EZ-G device includes technological advancements as a sex toy with a more realistic experience. The EZ-G device prototype uses sensors like a pressure sensor, temperature sensor, conductivity sensor, and heart rate sensor to determine what specifically enhances the users’ pleasure.
The EZ-G device uses artificial intelligence (AI) to transmit and receive data from the device’s sensors on conditions of the user’s sexual organs, such as moisture levels and pressure variations due to muscle contraction. The EZ-G prototype includes a Bluetooth component for controlling the adult device via an app installed on a smartphone or other portable device to collect user information about preferences and generate custom programs.
The data collected from the sensors is uploaded to the secured cloud, where it is combined with other antonymic user preferences, including the actual duration of operation of the adult device, lubrication level, and the ideal vibration level.
This information optimizes the operation of the device to satisfy the user sexually. The EZ-G device uses the collected secure data to learn the users’ responses and improve its operation to bring the user sexual satisfaction.
Wearable tech has seen tremendous growth in recent years. When most people think of wearables, they think of fitness trackers and smartwatches, but there is also an emerging trend in wearable sex toys.
The excitement of a sex toy and the thrill of clandestine public stimulation have contributed to this trend. Cannasoft intends to take advantage of the growth in the sextech market, which is expected to reach $62.32Bn by 2030.
According to Forbes, companies are working to innovate products that have an intelligent response to sexual activity to take advantage of this expected growth.
Yftah Ben Yaackov, CEO and Director of BYND Cannasoft said:
"The EZ-G device has evolved to provide treatment relief from sexual and mental problems, including the ability to have intercourse as it relates to anxiety and physical pain. The device is capable of enhancing sexual pleasure and reducing sexual pain by dispensing low concentrations of C-B-D oil lubricant in a controlled manner. It could be configured to use disposable capsules that include the C-B-D lubricant, which could be dispensed in accordance with data collected by the sensors. The sale of the disposable capsules containing the C-B-D lubricant would provide BYND Cannasoft with a revenue model much like the razor and the razor blade."
Find more key company details here.
And right now, BCAN has several potential catalysts to soak in right now. Check them out:
No. 1 BCAN Potential Catalyst - Low Float Volatility Could Approach Quickly In A Blink
According to the Market Watch website, BCAN has a low float.
The website reports this profile to have approximately 8.9Mn shares in its float.
Why is that important? It's important on one crucial level. Volatility.
Could more positive company news in 2023 provide a near term spark?
No. 2 BCAN Potential Catalyst - Game-Changing Product Launch Update Could Create A Significant Buzz
BYND Cannasoft Provides EZ-G Device Milestones for the Second Half of 2023
ASHKELON, Israel and VANCOUVER, British Columbia, July 25, 2023 (GLOBE NEWSWIRE) -- BYND Cannasoft Enterprises Inc. (Nasdaq: BCAN) (CSE: BYND) ("BYND Cannasoft" or the "Company") today announced several milestones for the second half of 2023 on the development of its groundbreaking EZ-G Device. The EZ-G device, a therapeutic solution utilizing AI and machine learning, could enhance therapeutic approaches for women's health issues by offering cutting-edge technology to cater to the evolving needs of consumers. Moreover, the company is actively negotiating with synergistic businesses, particularly those in the C-B-D oils sector, for a transformative transaction.
BYND Cannasoft is pleased to provide the following key milestones in the development of the EZ-G Device:
- Finishing the Prototype of the EZ-G Device in 60 Days: BYND Cannasoft plans to reiterate its commitment to innovation by accomplishing the development of the EZ-G Device's initial prototype within a 60-day timeline. The Company’s team of experts intends to create a prototype that showcases the technology's potential to disrupt the market.
- EZ-G Device Focus Group Experience within 60 Days: In line with BYND Cannasoft's customer-centric approach, the Company plans to engage a focus group to perform rigorous testing and evaluation of the EZ-G Device over the next 60 days. This process will provide valuable insights and user feedback, helping to refine the product to exceed customer expectations.
- Finalizing the EZ-G Device Prototype and Software by the End of the Fourth Quarter: Building upon insights gained from the focus group, BYND Cannasoft intends to build on its recent successful completion of the laboratory testing phase by fine-tuning the EZ-G Device's prototype and software. The Company is dedicated to refining user experience and functionality to introduce a superior product.
- Going to Market with the EZ-G Device in the First Quarter of 2024: With a meticulously developed and thoroughly tested product, BYND Cannasoft’s management believes the Company is on track for a market launch of the EZ-G Device in the first quarter of 2024. The Company anticipates that the product will set new industry benchmarks.
Yftah Ben Yaackov, CEO and Director of BYND Cannasoft said, "As part of the prototype development of the EZ-G device, numerous comprehensive experiments were conducted during the recent laboratory testing phase to assess the functionality and performance of the assembled sensors within the device that are capable of detecting indicators such as temperature, heart rate, contractions, and fluids. Our next phase will include completing the prototype, engaging in feedback from various focus groups, and solidifying strategic agreements to bring the EZ-G Device to market." Mr. Ben Yaackov continued, "This is an excellent example of our commitment to delivering exceptional products and experiences to our customers. Our relentless focus on innovation and customer satisfaction continues to drive our success, positioning BYND Cannasoft as a trailblazer in the women's health industry.”
In addition to these groundbreaking milestones, BYND Cannasoft is actively negotiating with several companies with synergistic business models, particularly those in the C-B-D oils sector. These discussions aim to establish transformative partnerships, opening doors for new opp's and amplifying the impact of both companies in the market.
Read the full article here.
No. 3 BCAN Potential Catalyst - Oversold Leaning Technicals May Be Suggesting A Healthy Reversal Nearing
As of close Friday, Barchart was reporting this profile to have several oversold leaning technicals.
These technicals could be signaling a healthy reversal could be approaching in the near term.
Here's the definition of a "reversal" from Investopedia:
"A reversal is a change in the price direction of an asset. A reversal can occur to the upside or downside. Following an uptrend, a reversal would be to the downside. Following a downtrend, a reversal would be to the upside. Reversals are based on overall price direction and are not typically based on one or two periods/bars on a chart."
Now, here are some key technicals (as of close Friday) that could signal BCAN to be leaning oversold and on the verge of a potential reversal.
- 9-Day Relative Strength Index: 12.40%
- 14-Day Relative Strength Index: 16.85%
When these numbers drop down to the 30% range and lower, they can be viewed as being in oversold territory. While in this territory, they can paint the picture of a profile that is undervalued.
- 14-Day Raw Stochastic: 8.44%
- 14-Day Williams %R: 91.56%
As the Raw Stochastic nears the 10% range and lower and the Williams %R nears the 90% range or higher, these technical indicators may also be viewed as oversold and undervalued.
Keep an eye on these technicals closely.
No. 4 BCAN Potential Catalyst - Lab Testing Completed, Product Continues Forward Movement Towards Future Launch
BYND Cannasoft Announces Successful Completion of Laboratory Testing Phase for EZ-G Device Optimization
ASHKELON, Israel and VANCOUVER, British Columbia, July 10, 2023 (GLOBE NEWSWIRE) -- BYND Cannasoft Enterprises Inc. (Nasdaq: BCAN) (CSE: BYND) (“BYND Cannasoft” or the “Company”) announced today the successful completion of the laboratory testing phase aimed at optimizing the various sensors in its innovative EZ-G device. ...
Throughout the laboratory testing phase, the Company conducted comprehensive experiments as part of the prototype development of the EZ-G device. The focus was on assessing the functionality and performance of the assembled sensors within the device, capable of detecting indicators such as temperature, heart rate, contractions, and fluids. By collecting and transferring data to the accompanying software, the information derived from these indicators was processed to optimize the device's usage for the user through machine learning technology.
This crucial milestone in the EZ-G device's development demonstrates the successful functionality of its capacitive sensor, the primary sensor within the device. The sensor has proven its capability to accurately detect the presence or absence of liquid within the device, specifically identifying changes in the fluid volume within the vagina. Consequently, the device can regulate the flow of oil or lubricating fluid during operation without requiring manual intervention from the user.
With the positive outcomes achieved during the trial, BYND Cannasoft is now committed to finalizing the EZ-G prototype model and progressing to the next phase of development: human trials involving focus groups of women of different age groups.
"We are thrilled with the successful completion of the laboratory testing phase for the EZ-G device," said Yftah Ben Yaackov, CEO and Director of BYND Cannasoft. "This accomplishment validates our dedication to harnessing advanced technology to improve women's health. We are excited to move forward with human trials, as we believe the EZ-G device has the potential to revolutionize therapeutic approaches for women's health issues."
The Company remains committed to ensuring the EZ-G device meets the highest safety, efficacy, and usability standards. Through continued research and development efforts, BYND Cannasoft aims to contribute to the well-being of women by providing an innovative solution for targeted health concerns.
Read the full article here.
No. 5 BCAN Potential Catalyst - But What About The Men? Another U.S. Patent Filed
U.S. Patent filed by BYND Cannasoft to Expand its Artificial Intelligence and Machine Learning Algorithm to a Male Treatment Device
ASHKELON, Israel and VANCOUVER, British Columbia, April 27, 2023 (GLOBE NEWSWIRE) -- BYND Cannasoft Enterprises Inc. (Nasdaq: BCAN) (CSE: BYND) ("BYND Cannasoft" or the "Company") announced today that its Zigi Carmel Initiatives & In-vest-ments LTD. subsidiary filed U.S. Provisional Patent Application 63461609 on April 25, 2023, covering the mechanical structure, operation, and controlling aspects of a male treatment device for external use capable of gathering information and creating custom programs according to the collected data from the sensors and uploading the data to the cloud. This U.S. Provisional Patent Application marks BYND Cannasoft's third potential candidate that could introduce new advanced haptic experiences to the fast-growing sexual wellness and sextech market.
The male treatment device utilizes artificial intelligence and machine learning algorithms to control its operational parameters based on the user's physiological parameters. The user, or a partner, can control the device with a smartphone app. Data collected by the device's sensors can be uploaded to the cloud where it will be stored to remember user preferences to create a custom experience for the user.
Yftah Ben Yaackov, CEO and Director of BYND Cannasoft, said, "As the multi-Bn-dollar sexual wellness and sextech market continues to grow, the industry is undergoing tremendous changes in consumer preferences as devices are increasingly connected online and enabled with interactive content. In this market, A.I., machine learning, and haptic technology have the potential to personalize the operational parameters of sexual wellness devices based on the physiological parameters of the user." Mr. Ben Yaackov continued, "As a corporate lawyer, I recognize the value of licensing our potential A.I. and machine learning patent portfolio to customers in the sexual wellness market and producing innovative new products. The Board of BYND Cannasoft is committed to protecting the company's I.P. covering this potentially lucrative market and bringing this innovative technology to market."
Read the full article here.
BCAN Recap - The Top Potential Breakout Catalysts To Know Right Now
No. 1 - Low Float Volatility Could Approach Quickly In A Blink
No. 2 - Game-Changing Product Launch Update Could Create A Significant Buzz
No. 3 - Oversold Leaning Technicals May Be Suggesting A Healthy Reversal Nearing
No. 4 - Lab Testing Completed, Product Continues Forward Movement Towards Future Launch
No. 5 - But What About The Men? Another U.S. Patent Filed
Coverage is officially reinitiated on BCAN. When time permits, do this: